First Trust Advisors LP Eagle Pharmaceuticals, Inc. Transaction History

First Trust Advisors LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $6,368 - $11,441	359 Added 1.27%	28,731 $558,000
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $52,951 - $72,032	2,113 Added 8.05%	28,372 $804,000
Q4 2022 Feb 09, 2023	SELL	$24.98 - $39.77 $47,237 - $75,205	-1,891 Reduced 6.72%	26,259 $767,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $301,003 - $536,838	11,393 Added 67.99%	28,150 $744,000
Q2 2022 Aug 12, 2022	SELL	$41.26 - $51.35 $35,318 - $43,955	-856 Reduced 4.86%	16,757 $745,000
Q1 2022 May 13, 2022	SELL	$44.58 - $52.6 $45,114 - $53,231	-1,012 Reduced 5.43%	17,613 $872,000
Q4 2021 Feb 08, 2022	BUY	$45.82 - $56.9 $94,251 - $117,043	2,057 Added 12.42%	18,625 $948,000
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $725,512 - $924,163	16,568 New	16,568 $924,000
Q1 2019 May 09, 2019	SELL	$38.66 - $51.82 $291,921 - $391,292	-7,551 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$36.72 - $67.73 $277,272 - $511,429	7,551 New	7,551 $304,000
Q4 2017 Feb 08, 2018	SELL	$49.6 - $60.87 $1.07 Million - $1.31 Million	-21,472 Closed	0 $0
Q3 2017 Oct 24, 2017	BUY	$46.62 - $60.36 $1 Million - $1.3 Million	21,472	21,472 $1.28 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.